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1192Objective: Recent studies have suggested that human solid tumors may contain subpopulations of cancer stem
cells with the capacity for self-renewal and the potential to initiate and maintain tumor growth. The aim of this
study was to use human esophageal cell lines to identify and characterize putative esophageal cancer stem cell
populations.
Methods: To enrich stemlike cells, Het-1A (derived from immortalized normal esophageal epithelium), OE33,
and JH-EsoAd1 (each derived from primary esophageal adenocarcinomas) were cultured using serum-free me-
dia to form spheres. A comprehensive analysis of parent and spheroid cells was performed by flow cytometry,
Western blot analysis, immunohistochemistry and polymerase chain reaction array to study cancer stem cell-
related genes, colony formation assays to assess clonogenicity, xenotransplantation to assess tumorigenicity,
and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays to assess chemosensitivity to
5-fluorouracil and Cisplatin.
Results: For all cell lines, clonogenicity, tumorigenicity, and chemoresistance to 5-fluorouracil and Cisplatin
were significantly higher than for spheroid cells compared with parent cells. Spheroids exhibited an increased
frequency of cells expressing integrin a6bri/CD71dim, and Achaete-scute complex homolog 2 messenger RNA
and protein were also significantly overexpressed in spheroid cells compared with parent cells.
Conclusions: The higher clonogenicity, tumorigenicity, and drug resistance exhibited by spheroids derived from
Het-1A, OE33, and JH-EsoAd1 reflects an enrichment of stemlike cell populations within each esophageal
cell line. Esophageal cells enriched for integrin a6bri/CD71dim and/or overexpressing Achaete-scute complex
homolog 2 would appear to represent at least a subpopulation of stemlike cells in Het-1A, OE33, and
JH-EsoAd1. (J Thorac Cardiovasc Surg 2012;144:1192-9)Biologic models have considered the progression of Bar-
rett esophagus (BE) to esophageal adenocarcinoma
(EADC) as a multistep process associated with clonal evo-
lution of tumor cell populations.1 More recently, increas-
ing evidence suggests that human solid tumors may arise
from a small subpopulation of cancer stemlike cells, with
capacity for asymmetric cell division, self-renewal, differ-
entiation, and resistance to chemotherapeutic agents.2,3
Although the establishment of tumors and serial
transplantation in immunocompromised mice remains the
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The Journal of Thoracic and Cardiovascular Surcell (CSC) subpopulation, the identification of cell
surface markers and the ability of CSCs to form spheres
in vitro has greatly facilitated the identification of cancer
stemlike cells. Using such approaches, putative CSCs
have now been reported in various malignancies of the
gastrointestinal tract,4,5 but have yet to be identified in
human esophageal cancer.6-8 In the most comprehensive
study of human BE and EADC tissues performed to
date, a subpopulation identified as tumor-initiating stem-
like cells did not express any of the common cell surface
antigens (CD24, CD29, CD34, CD44, CD133, CD166, ep-
ithelial cell adhesion molecule [EpCAM], and b-catenin)
established previously as CSC markers in other human
malignancies.8
Therefore, in view of the current lack of progress in
identifying CSCs in human esophageal tissues, we ex-
plored an alternative strategy using human cell lines de-
rived from primary EADC tumors and normal esophageal
epithelium. Stem-like cells were enriched by sphere cul-
ture, and a comprehensive analysis of parent and spheroid
cells was performed by flow cytometry, Western blot anal-
ysis, immunohistochemistry, polymerase chain reaction
(PCR) -array to identify CSC-related genes; colony forma-
tion assays, xenotransplantation, and chemosensitivity as-
says to identify and characterize putative esophageal
CSC subpopulations.gery c November 2012
Abbreviations and Acronyms
Ascl2 ¼ Achaete-scute complex homolog 2
BE ¼ Barrett esophagus
CDDP ¼ cis-diamminedichloroplatinum(II),
Cisplatin
CI ¼ confidence interval
CSC ¼ cancer stem cell
DMEM ¼ Dulbecco’s Modified Eagle Medium
EADC ¼ esophageal adenocarcinoma
EDTA ¼ ethylenediamine tetraacetic acid
ELDA ¼ extreme limiting dilution assay
EpCAM ¼ epithelial cell adhesion molecule
5-Fu ¼ 5-fluoruracil
FBS ¼ fetal bovine serum
IHC ¼ immunohistochemistry
Lgr5 ¼ leucine-rich repeat containing G
protein-coupled receptor
mRNA ¼ messenger ribonucleic acid
MTT ¼ 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide
PBS ¼ phosphate-buffered saline
PCR ¼ polymerase chain reaction
RPMI ¼ Roswell Park Memorial Institute
Wnt ¼ wingless type
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Human Esophageal Cell Lines
Two primary EADC cell lines (OE33 and JH-EsoAd1) and 1 immortal-
ized normal esophageal epithelial cell line (Het-1A) were studied. OE339
and Het-1A10 were purchased from the American Type Culture Collection
(Manassas, Va) and the European Cell Culture Collection (Porton Down,
UK), respectively. JH-EsoAd111 was generously provided by Drs Eshle-
man and Maitra (Johns Hopkins University, Baltimore, Md). Parent cell
lines were cultured in monolayers utilizing Dulbecco’s Modified Eagle
Medium (DMEM) with 10% fetal bovine serum (FBS) for Het-1A,
Roswell Park Memorial Institute (RPMI) 1640 medium with
10% FBS for OE33, and RPMI with 20% FBS for JH-EsoAd1. Cells
were cultured under standard conditions (37C and 5% CO2) and passaged
using 0.25% trypsin/ethylenediamine tetraacetic acid (EDTA) upon 70%
to 80% confluence.
Sphere Culture
From each parent cell line, 53 104 cells were seeded into 25-cm2 Ultra-
LowAttachment Cell Culture Flasks (Corning, NY) containing 5 mL serum-
free sphereculturemedium,comprisingDMEM/F-12, basicfibroblast growth
factor (20 ng/mL), epidermal growth factor (20 ng/mL), and 13B27 supple-
ment.12Cellswere cultured for 2 to 4weeks until spheroids (eachwith 50-100
cells per sphere) formed. Parent cells were detached by incubation with
0.05% trypsin/EDTA, and spheroid cells were isolated using a 50-mm cell
strainer and dissociated with 0.25% trypsin/EDTA. Detached parent cells
and dissociated spheroid cells were washed with phosphate-buffered saline
(PBS), counted, and suspended in fresh culture medium or PBS.
Flow Cytometry and Cell Sorting
Parent cells were stained with primary antibodies (Abcam, Cam-
bridge, Mass) to the following CSC-related markers: CD24, CD34,The Journal of Thoracic and CarCD44, CD71, CD133, EpCAM, anti-integrin a6, Musashi 1, and
Oct4. For cytoplasmic and nuclear markers, cells were fixed and per-
meabilized with IntraPrep Permeabilization Reagent (Beckman Coulter,
Mississauga, Ontario, Canada) before staining. For unconjugated anti-
bodies, a fluorescein isothiocyanate-conjugated secondary antibody
(goat antirabbit immunoglobulin G) was used. Antibody-stained cells
were measured with a Coulter Epics XL and XL-MCL Flow Cytome-
ter, and data were analyzed using Flowjo software (FlowJo 8.86, Ash-
land, Ore) to determine the intensity and percentage of positive-staining
cells.
Based on flow cytometry results obtained from parent cells, Musashi
1 and integrin a6/CD71 were evaluated further in spheroid cells.
Fluorescence-activated cell sorting was performed using the Epics
Elite Esp cell sorting system (Beckman Coulter, Brea, Calif) to isolate 4
cell subsets reflecting integrin a6/CD71 expression—integrin
a6bri/CD71dim, integrin a6bri/CD71bri, integrin a6dim/CD71dim, and integ-
rin a6dim/CD71bri—using PE-conjugated anti-CD71 and fluorescein
isothiocyanate-conjugated anti-integrin a6 antibodies (BD Bioscience,
San Diego, Calif). Cell subsets were harvested, then washed with PBS
for downstream colony and sphere formation assays.
Sphere Formation Assay
Sphere formation assays13 were performed using 96-well Ultra-LowAt-
tachment Cell Culture Plates. Cells were mixed with serum-free sphere cul-
ture media and seeded into each well at 250, 50, 10, and 2 cells per well
(12wells for each concentration). Plateswere incubated for 2 to 4weeks un-
til spheres formed;wells containing spheroid cells were counted as positive.
The number of positive wells (per 12 wells at each cell dose) was used to
quantitate sphere-forming ability using extreme limiting dilution analysis
(ELDA).14
Colony Formation Assay
Colony formation assays13 were performed using 96-well cell culture
plates coated with 0.1 mL bottom agar mixture (DMEM, 10% FBS,
0.6% agar). After the bottom layer solidified, cells were mixed with top
agar (DMEM, 10% FBS, 0.3% agar), and seeded into each well at 100,
33, 10, and 3 cells per well (12 wells for each concentration). Plates
were incubated for 4 weeks until colonies were large enough to be visual-
ized. Colonies were stained with 0.005% Crystal Violet for 1 hour and
counted; wells containing clones were counted as positive. The number
of positive wells (per 12 wells at each cell dose) was used to quantitate clo-
nogenicity using ELDA.14
Tumorigenic Assay
All animal studies were performed in accordance with the Guide to the
Care and Use of Experimental Animals of the Canadian Council on An-
imal Care, and were approved by the University of Saskatchewan Com-
mittee on Animal Care and Research Ethics Board (protocol no.
20090037). Het-1A, OE33, and JH-EsoAd1 cells were implanted into
several species of nude mice, including Hsd:Athymic Nude-Foxn1nu,
BALB/c OlaHsd-Foxn1nu, and HsdOla:ICRF-Foxn1nu (Harlan Laborato-
ries Inc, Indianapolis, Ind); and Jax Nu/J and NOD.Cd-Prkdcscid
Il2rgtm1Wjl/SzJ mice (The Jackson Laboratory, Bar Harbor, Mass).
Seven-week-old BALB/c OlaHsd-Foxn1nu mice and NOD.Cd-Prkdcscid
Il2rgtm1Wjl/SzJ mice were selected for inoculation with OE33 and JH-
EsoAd1, respectively. Parent and spheroid cells (1 3 107, 1 3 106, and
1 3 105 cells for OE33; 1 3 106, 2 3 105, and 4 3 104 cells for JH-
EsoAd1) were injected subcutaneously into the flank of each mouse.
The incidence of tumors (per 5 inoculations at each cell dosage) was re-
corded weekly and was used to calculate tumorigenicity using ELDA.14
When each animal was euthanized, tumors were excised, measured (to
calculate tumor volume), and bisected. One part was fixed in 10% forma-
lin and embedded in paraffin and the other was snap frozen in liquid ni-
trogen and stored at80C.diovascular Surgery c Volume 144, Number 5 1193
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Formalin-fixed xenograft tumor sections (4 mm thick) derived from
OE33 and JH-EsoAd1 parent and spheroid cells were first stained with he-
matoxylin–eosin to determine histopathology. Immunohistochemistry
(IHC) was performed on adjacent serial sections to study protein expres-
sion and distribution using primary antibodies against CD44 (1:100 dilu-
tion), CD71 (1:10 dilution), CD133 (1:50 dilution), and integrin a6
(1:150 dilution). Tissue staining was detected using the EnVision Dual
Link Kit (Dako, Markham, Ontario, Canada) following the manufacturer’s
instructions. Controls were run in parallel with test sections, and included
sections that were stained with nonimmune normal goat serum or with pre-
absorbed antiserum (negative controls). Interpretation of sections was per-
formed by 2 investigators experienced in IHC analysis, and included an
assessment of subcellular distribution (cytoplasmic or nuclear) of staining,
intensity (0,þ, 2þ, 3þ) and percentage of immunopositive cells (per high-
power field).
Chemosensitivity Assay
Chemosensitivity of Het-1A, OE33, and JH-EsoAd1 to 5-fluorouracil
(5-Fu) and Cisplatin (cis-diamminedichloroplatinum(II) [CDDP]), the
2 most widely used chemotherapeutic agents for EADC in current
clinical practice, was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assays. Parent and spheroid cells
were seeded in 96-well plates at 2 3 104 per well in 100 mL medium
and, after 24 hours of incubation, were treated with serially diluted 5-Fu
or CDDP (1.00-4.00 mg/mL) for an additional 72 hours. Cell proliferation
in each well was determined using MTT assays.15 Briefly, 10 mL MTT
solution was added to each well, and the plate was incubated for 4 hours
at 37C. A total of 100 mL of solubilization solution was added to each
well, followed by overnight incubation at 37C. The plate was read at
a wavelength of 570 nm/650 nm using a standard SpectraMax microplate
reader. The ratio of absorbance in treated wells versus untreated control
wells reflected cell proliferation, which was expressed as a percentage.
All experiments were repeated at minimum in triplicate.
PCR Array
Total RNAwas extracted from parent and spheroid cells using the All-
Prep DNA/RNA Mini Kit (Qiagen, Mississauga, Ontario, Canada). cDNA
was synthesized by reverse transcription of 2 mg total RNA by use of
random primers and Superscript Reverse Transcriptase III (Invitrogen,
Burlington, Ontario, Canada).
Gene expression profiles were determined using PCR arrays (SABio-
sciences, Frederick, Md) to detect messenger ribonucleic acid (mRNA) ex-
pression of 253 stem cell, drug resistance, and wingless-type (Wnt)-related
genes. All reagents and materials for each PCR array were purchased from
SABiosciences, and experiments were performed on the StepOnePlus
Real-Time PCR System (Applied Biosystems, Foster City, Calif). Fold
changes of gene expression in spheroid cells relative to corresponding par-
ent cells were calculated using Web-based software from SABiosciences
(http://www.sabiosciences.com/pcr/arrayanalysis.php). Upregulation or
downregulation of a gene was defined as a change > or <2-fold,
respectively.
Western Blot Analysis
Based on results of the PCR stem cell array, we utilized Western blot
analysis to study expression of Achaete-scute complex homolog
2 (Ascl2) protein in cell lines and xenografts (parent and spheroid cells).
We also studied expression of the leucine-rich repeat containing
G protein-coupled receptor (Lgr5), a related Wnt signaling pathway tar-
get gene and potential CSC marker. Whole-cell lysates of parent and
spheroid cells were isolated using RIPA buffer with proteinase inhibitor
cocktail (Sigma-Aldrich, Oakville, Ontario, Canada). Protein samples
were heated at 95C for 10 minutes, separated on an 8% or 12.5%1194 The Journal of Thoracic and Cardiovascular Sursodium dodecyl sulfate polyacrylamide gel electrophoresis gel, and trans-
ferred to a nitrocellulose film by electroblotting. Primary antibodies
against Ascl2, Lgr5, and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; a loading control) were purchased from Abcam). The Licor
2-color Western blotting kit (Lincoln, Neb) was used to detect specific
bands, and all experiments were performed according to standard proto-
cols from Abcam and Licor. The stained bands were recorded and ana-
lyzed quantitatively with the Licor Oldssey image system and Quantity
One software (Bio-Rad, Mississauga, Ontario, Canada). The relative pro-
tein expression of Ascl2 and Lgr5 was expressed as the ratio of the nor-
malized volume of a specific band for each cell type versus the
normalized volume of the band for parent Het-1A cells.Statistical Analysis
Data were expressed as percentages, mean ( standard deviation) or
median and 95% confidence intervals), and analyzed using the Student t
test, Mann-Whitney U test, or Wilcoxon test as appropriate. Kaplan-
Meier and log-rank tests were used for comparing tumor frequency in
animals. All analyses were conducted using SPSS 15.0 (Chicago, Ill).
The estimated frequencies of sphere, clone, and tumor formation for
each cell type (parent and spheroid) were quantitated using ELDA incorpo-
rating an online Web tool, as reported previously.14 Statistical significance
was set at P<.05.
RESULTS
Flow Cytometry of Parent Cells and Spheroid Cells
Flow cytometric analysis of parent cells revealed consis-
tent negativity for CD24, CD34, and CD133, and consistent
high positivity for CD44 (Het-1A, 90%; OE33, 84%;
JH-EsoAd1, 98%) and Oct4 (Het-1A, 63%; OE33, 69%;
JH-EsoAd1, 99%). CD71 was highly positive in Het-1A
(73%) and JH-EsoAd1 (89%), but only moderately posi-
tive in OE33 (41%). Moderate positivity (Het-1A, 16%;
OE33, 34%; JH-EsoAd1, 43%) was found for Musashi 1.
EpCAM was negative in Het-1A and OE33, but slightly
positive (6%) in JH-EsoAd1. Integrin a6 was slightly pos-
itive in Het-1A (5%), low in OE33 (0.2%), and moderately
positive in JH-EsoAd1 (44%). Less than 1% of parent cells
were positive for integrin a6bri/CD71dim (Het-1A, 0.11%;
OE33, 0.01%; JH-EsoAd1, 0.21%).
Flow cytometry was performed on Het-1A, OE33, and
JH-EsoAd1 spheroid cells to evaluate further Musashi
1 and integrin a6/CD71. No differences in Musashi 1 stain-
ing were found between parent and spheroid cells of any
cell line. However, as illustrated in Figure 1, significant dif-
ferences in integrin a6bri/CD71dim staining were seen for
parent cells (Het-1A, 0.11%; OE 33, 0.01%; JH-EsoAd1,
0.21%) and spheroid cells (Het-1A, 21.3%; OE33,
5.73%; JH-EsoAd1, 11.3%).Clonogenicity and Tumorigenicity of Parent Cells
and Spheroid Cells
All Het-1A, OE33, and JH-EsoAd1 parent and spheroid
cells formed colonies in soft agar. As summarized in
Table 1, spheroid cells demonstrated significantly en-
hanced clonogenicity compared with parent cells for all
cell lines.gery c November 2012
FIGURE 1. Flow cytometry was used to study expression of integrin a6 (vertical axis) and CD71 (horizontal axis) in Het-1A, OE33, and JH-EsoAd1 parent
cells (A) and spheroid cells (B). Relative to unstained cells (top row, A and B), significant differences in staining were seen for each cell line between parent
cells (lower row, A) and spheroid cells (lower row, B). Significant differences in integrin a6bri/CD71dim staining (upper left quadrant of each panel) were
seen between parent cells (Het-1A, 0.11%; OE33, 0.01%; JH-EsoAd1, 0.21%) compared with spheroid cells (Het-1A, 21.3%; OE33, 5.73%; JH-EsoAd1,
11.3%). FITC, Fluorescein isothiocyanate conjugate.
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of cell numbers implanted, resulted in any xenograft tumor
formation. At 10 weeks, of 15 parent or spheroid cell inoc-
ulations, 1 tumor (6.7%) resulted from OE33 parent cells,
and 4 tumors (26.7%) resulted from OE33 spheroid cells.
For JH-EsoAd1, 1 tumor (6.7%) resulted from inoculation
of parent cells and 8 tumors (53.3%) resulted from inocula-
tion of JH-EsoAd1 spheroid cells. At study termination
(29 weeks for OE33, 13 weeks for JH-EsoAd1), OE33 par-
ent cell inoculation resulted in 2 tumors (13.3%; median
volume, 1.7 mm3), and OE33 spheroid cell inoculation re-
sulted in 6 tumors (40.0%; median volume, 500 mm3);
JH-EsoAd1 parent cell inoculations resulted in 6 tumorsThe Journal of Thoracic and Car(40.0%; median volume, 275 mm3), and JH-EsoAd1 spher-
oid cell inoculation resulted in 13 tumors (86.7%; median
volume, 1098 mm3). Kaplan-Meier analysis confirmed
a greater frequency of tumors resulting from spheroid cell
inoculation compared with parent cell inoculation at
study termination for each cell line (OE33, P ¼ .12;
JH-EsoAd1, P < .01), which was also confirmed by
ELDA (OE33, P ¼ .06; JH-EsoAd1, P<.01; Table 1).
Xenograft Tumor Histology and IHC
Histologic examination of OE33 and JH-EsoAd1 xeno-
grafts confirmed that adenocarcinomas resulted from
inoculation of parent cells and spheroid cells (OE33 anddiovascular Surgery c Volume 144, Number 5 1195
TABLE 1. Clonogenicity and tumorigenicity of Het-1A, OE33, and JH-EsoAd1 parent and spheroid cells determined by extreme limiting dilution
analysis
Cell line Parent cells, median frequency (95% CI) Spheroid cells, median frequency (95% CI) P value
Clonogenicity
Het-1A 1/51.46 (1/92.80-1/28.50) 1/8.13 (1/15.20-1/4.30) <.01
OE33 1/49.40 (1/85.8-1/28.5) 1/15.10 (1/27.50-1/8.60) <.01
JH-EsoAd1 1/196.20 (1/409.00-1/94.20) 1/72.40 (1/124.00-1/42.20) <.05
Tumorigenicity
OE33 1/36.10 3 105 (1/145.00 3 105-1/8.98 3 105) 1/8.69 3 105 (1/20.50 3 105-1/3.69 3 105) .06
JH-EsoAd1 1/4.58 3 105 (1/1080 3 105-1/1.94 3 105) 1/0.41 3 105 (1/1.12 3 105-1/0.15 3 105) <.05
Median frequencies estimated from extreme limiting dilution analysis.14 CI, Confidence interval.
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were of higher grade compared with tumors resulting from
inoculation of parent cells. IHC analysis revealed consis-
tently negative staining in all control sections, and tissues
stained for CD133 and CD71. Positive cell membrane stain-
ing was seen for CD44 in xenografts derived from parent
cells (OE33: 3þ, 60%; JH-EsoAd1: 2þ, 30%) and spheroid
cells (OE33: 2þ, 30%; JH-EsoAd1: 3þ, 90%) for all cell
lines. Cytoplasmic and cell membrane staining was consis-
tently positive (2þ, 80%) for integrin a6 in all xenograft tu-
mors arising from parent and spheroid cells of OE33 and
JH-EsoAd1.Characterization of Integrin a6/CD71 Cell
Subpopulations
As summarized in Table 2, ELDA showed that integrin
a6bri/CD71dim subpopulations of Het-1A, OE33, and
JH-EsoAd1 cell lines contained more clonogenic and
sphere-forming cells compared with each of the other
subpopulations.TABLE 2. Clonogenicity and sphere formation of Het-1A, OE33, and JH-E
a6 and CD71
Cell line Clonogenicity
Subpopulation Median frequency (95% CI)
Het-1A
Integrin a6bri/CD71dim 1/84.1 (1/145-1/48.9)
Integrin a6bri/CD71bri 1/331.9 (1/820-1/134.4)
Integrin a6dim/CD71dim 1/170.1 (1/339-1/86)
Integrin a6dim/CD71bri 1/186.7 (1/380-1/91.8)
OE33
Integrin a6bri/CD71dim 1/112 (1/202-1/61.9)
Integrin a6bri/CD71bri 1/395 (1/1049-1/148.6)
Integrin a6dim/CD71dim 1/544 (1/1687-1/175.5)
Integrin a6dim/CD71bri 1/312 (1/753-1/129.4)
JH-EsoAd1
Integrin a6bri/CD71dim 1/124 (1/219-1/69.9)
Integrin a6bri/CD71bri 1/350 (1/1086-1/112.8)
Integrin a6dim/CD71dim 1/890 (1/2730-1/290.5)
Integrin a6dim/CD71bri 1/1636 (1/6577-1/407.1)
P values presented with reference to integrin a6bri/CD71dim cells. Median frequencies est
1196 The Journal of Thoracic and Cardiovascular SurChemosensitivity of Parent Cells and Spheroid Cells
As shown in Figure 2, spheroid cells of all cell lines
exhibited lower proliferation rates compared with corre-
sponding parent cells: Het-1A: 0.66  0.08 (sphere) verses
0.13  0.01 (parent), P<.01; OE33: 0.47  0.09 (sphere)
verses 0.29  0.06 (parent), P<.05; JH-EsoAd1: 0.68 
0.08 (sphere) verses 0.34  0.03 (parent), P<.01.
Compared with parent cells, all spheroid cells were resis-
tant to 5-Fu. Het-1A spheroid cells were also resistant
to CDDP, as was OE33 at higher doses (4 mg/mL).
JH-EsoAd1 spheroid cells exhibited similar chemosensitiv-
ity to CDDP to their parent cells at all doses studied.mRNA Expression Profile of CSC-Related Genes
PCR array of 253 CSC related genes revealed different
gene expression profiles among each cell line. Table 3 sum-
marizes the 3 most frequently upregulated and downregu-
lated genes in spheroid cells (relative to parent cells) for
each cell line. Only 1 gene, Ascl2, was found to be consis-
tently upregulated in all cell lines: Het-1A, 2.5-fold; OE33,soAd1 parent cell subpopulations expressing different levels of integrin
Sphere formation
P value Median frequency (95% CI) P value
— 1/7.09 (1/12.80-1/3.94) —
<.01 1/38.34 (1/68.10-1/21.60) <.01
.09 1/27.77 (1/48.60-1/15.85) <.01
.06 1/18.29 (1/31.90-1/10.48) .02
— 1/7.09 (1/12.80-1/3.94) —
.02 1/28.24 (1/49.50-1/16.12) <.01
<.01 1/86.67 (1/15.50-1/49.90) <.01
.04 1/17.47 (1/30.50-1/10.00) .03
— 1/6.62 (1/11.90-1/3.69) —
.07 1/8.27 (1/14.90-1/4.59) .61
<.01 1/29.17 (1/51.20-1/16.63) <.01
<.01 1/20.03 (1/34.90-1/11.50) <.01
imated from extreme limiting dilution analysis.14 CI, Confidence interval.
gery c November 2012
FIGURE 2. Cellular proliferation rates were significantly (P<.005) lower
for spheroid cells compared with original (parent) cells for each cell line.
Bars reflect standard error. MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide.
Zhao et al Evolving Technology/Basic Scienceþ10.2-fold; and JH-EsoAd1, þ4.8-fold upregulation in
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Western blot analysis of Ascl2 protein expression re-
vealed a predicted positive 28-kDa band in each cell line
(Figure 3, A). An additional higher molecular weight band
(estimated, 48 kDa) was also found in each tumor cell
line (OE33 and JH-EsoAd1 parent and spheroid cells), but
was not detected in Het-1A. Quantitative analysis showed
that relative to Ascl2 protein expression in Het-1A parent
cells, Ascl2 protein was significantly (P < .05) overex-
pressed in OE33 parent cells and underexpressed in
JH-EsoAd1 parent cells (Figure 3, B). For each cell line,
Ascl2 protein expression was significantly higherTABLE 3. PCR array of stem cell related genes summarizing the 3
most frequently upregulated and downregulated genes in Het-1A,
OE33, and JH-EsoAd1 spheroid cells relative to parent cells
Gene expression Het-1A OE33 JH-EsoAd1
Upregulated
(-fold*)
SFRP 4 (þ36.6) CD 3 (þ49.2) FOS (þ39.9)
BMP 3 (þ21.3) WNT 1 (þ32.5) CYP 3A5 (þ32.5)
FORK A2 (þ19.4) CCN A2 (þ30.2) DKK 1 (þ8.8)
Downregulated
(-fold*)
ABC B1 (68.4) WNT 5B (61.7) ALD 1 (21.4)
FZD 4 (57.8) FORK A2 (45.2) FZD 2 (17.8)
MYO 1 (24.2) BMP 2 (13.9) FGF 1 (17.1)
SFRP, Secreted frizzled-related protein; CD, cluster of differentiation marker; FOS,
v-fos oncogene; BMP, bone morphogenic protein; WNT, wingless-type signaling
pathway; CYP, cytochrome 450 family; FORK, forkhead box; CCN, cyclin; DKK,
Dickkopf homolog; ABC, adenosine triphosphate-binding cassette family;ALD, alde-
hyde dehydrogenase; FZD, frizzled homolog; MYO, myogenic differentiation; FGF,
fibroblast growth factor. *Fold change: upregulation (þ) or downregulation ().
The Journal of Thoracic and Carin spheroid cells compared with parent cells (Het-1A:
1.71  0.42 vs 1.00  0.00, P<.05; OE33: 4.70  1.05
vs 2.74  0.63, P<.05; JH-EsoAd1: 1.29  0.25 vs 0.27
 0.09, P<.01). Similar patterns of Ascl2 protein expres-
sion were also found in OE33 and JH-EsoAd1 xenografts
derived from parent cells and spheroid cells. Lgr5 expres-
sion was consistently negative in all cell lines and xeno-
grafts (parent and spheroid cells).
DISCUSSION
In keeping with recent results from a comprehensive
evaluation of 17 surgically resected human EADCs in
which IHC was used to stain for a panel of CSC markers
(CD24, CD29, CD34, CD44, CD133, CD166, EpCAM,
and b-catenin),8 we found that all esophageal cell lines ex-
hibited consistent high positivity for CD44 and Oct4, and
negativity for CD24, CD34, and CD133. Although EpCAM
was consistently negative in Het-1A and OE33, slight pos-
itivity (6%) was seen in JH-EsoAd1. Moderate positivity
was also seen for Musashi 1 in each parent cell line (Het-
1A, 16%; OE33, 34%; JH-EsoAd1, 43%), comparable
with expression levels reported in human esophageal tis-
sues.16 To date, relatively few studies have evaluated esoph-
ageal cancer cell lines specifically, derived predominantly
from squamous cell carcinomas.17,18 Upregulation of
several key stem cell-related genes (including Oct4), Wnt
and Notch signal pathway-related genes was reported re-
cently in side populations of EC9706 and EC109,17 and in-
creased expression of b-catenin and b1 integrin were
reported in a radio-resistant cell line derived from TE-2,
which also contained a higher percentage of side population
cells compared with the parent cell line.18
We found that spheroid cells derived from Het-1A,
OE33, and JH-EsoAd1 enriched significantly for integrin
a6bri/CD71dim compared with parent cells (Figure 1). Our
finding of enhanced in vitro clonogenicity and spheroge-
nicity (Table 2) for cells expressing integrin a6bri/
CD71dim further supports the notion that these markers re-
flect at least a subpopulation of esophageal stemlike cells
in each cell line studied. Indeed, integrin a6bri/CD71dim
has been reported to enrich human corneal epithelial/
stem progenitor cells,19 and keratinocyte stem cell popu-
lations.20,21 A minor subpopulation of undifferentiated
cells enriched for integrin a6bri/CD71dim has also been
reported in the basal layer of the mouse esophagus,
a potential murine CSC niche.22 Although recent evidence
had been presented to support a central role for integrins
in human embryonic stem cell culture, the precise
molecular pathways underlying the contribution of in-
tegrins to CSC biology have yet to be defined. By regulat-
ing cellular adhesion in the extracellular matrix, it has
been suggested that integrins have a central role in main-
taining stem cells in their microenvironment, and have
been implicated specifically in the bone marrowdiovascular Surgery c Volume 144, Number 5 1197
FIGURE 3. Expression of Achaete-scute complex homolog 2 (Ascl2) in
parent and spheroid cells of Het-1A, OE33 and JH-EsoAd1. A, Western
blot analysis illustrating increased Ascl2 protein expression in spheroid
cells relative to parent cells of each cell line. B, Relative to Ascl2 protein
expression in Het-1A parent cells, Ascl2 protein expression was signifi-
cantly (P < .05) overexpressed in OE33 parent cells, whereas JH-
EsoAd1 parent cells underexpressed Ascl2 protein (the fold change relative
to Het-1A parent cells is shown on the vertical axis). For each cell line,
Ascl2 protein was significantly (P<.05) overexpressed in spheroid cells
relative to parent cells. Bars reflect standard error. GAPDH, Glyceralde-
hyde 3-phosphate dehydrogenase; P, parent cells; S, spheroid cells.
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chemoresistance.
PCR array was also used to study the expression of
CSC-related genes in esophageal cell lines and spheres;
the 3 most frequently up- and downregulated genes are
shown in Table 3. However, relative to parent cells,
only Ascl2 mRNA was found to be consistently upregu-
lated in Het-1A, OE33, and JH-EsoAd1 spheroid cells.
Corresponding overexpression of Ascl2 protein was con-
firmed subsequently by Western blot analysis in each
cell line (Figure 3), and in OE33 and JH-EsoAd1 xeno-
grafts. In addition to the predicted positive 28-kDa band
in each cell line, an additional band of higher molecular
weight (estimated, 48 kDa) was found only in each of
the tumor cell lines (OE 33 and JH-EsoAd1 parent and
spheroid cells), but was not detected in Het-1A. A higher
molecular weight band, most likely a consequence of
overexpression of a long mRNA Ascl2 transcript, has
been reported previously to encode an open reading frame
for an uncharacterized protein,23 although further charac-
terization will be required to evaluate its specific role in
human malignancy.1198 The Journal of Thoracic and Cardiovascular SurTo our knowledge, this is the first report of Ascl2 mRNA
and protein expression in human esophageal cell lines and
xenografts. As a direct transcriptional target of Wnt,
Ascl2 has been implicated in the maintenance of human in-
testinal stem cells, in addition to regulating cell prolifera-
tion by modulating progression through the cell cycle G2/
M checkpoint.23 Relative to low levels of expression in nor-
mal colonic epithelia, Ascl2 mRNA has been reported to be
overexpressed in primary colorectal adenocarcinomas, and
in colorectal liver metastases with 11p15.5 gain, in which
the induction by Ascl2 of several downstream target genes
appeared to confer a unique CSC expression signature.24
Ascl2 has also recently been implicated in drug resistance
to various anticancer agents (including 5-Fu)25—an impor-
tant characteristic of the CSC phenotype limiting the clini-
cal efficacy of many current cytotoxic chemotherapeutic
agents.
In summary, we have demonstrated that human esopha-
geal cell lines derived from normal esophageal epithelia
and primary EADCs, when grown in serum-free media to
form spheroids, each exhibited increased clonogenicity, tu-
morigenicity, and drug resistance, reflecting an enrichment
of stemlike cell populations. Integrin a6bri/CD71dim would
appear to define at least a subpopulation of cancer stemlike
cells in human esophageal cell lines, with the potential to
direct future clinically relevant therapeutic strategies for hu-
man esophageal malignancy. Our novel finding of Ascl2
overexpression in esophageal cell lines and xenografts rep-
resents a particularly promising area for further investiga-
tion of esophageal tumor/CSC biology.References
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Dr Jules Lin (Ann Arbor, Mich). Congratulations on your very
nice presentation. I have several questions that I would like to ask
individually. Het-1A is a normal squamous esophageal cell line.
Why did you choose to use a normal cell line? In your comparison
you looked at 2 tumor cell lines and a normal squamous cell line
looking for a commonality between the 3. Would it have been
more appropriate to compare the tumor cell lines to find something
that was overexpressed when compared to the normal cell line?
Dr Casson. Esophageal cell lines are quite notoriously difficult
to get a hold of. I would question whether Het-1A, which has beenThe Journal of Thoracic and Cararound for 20-odd years, is truly normal at this point. It was orig-
inally derived from normal epithelium but has been immortalized.
We put that in—really as, in quotes—the ‘‘negative control.’’ But,
again, I would caution the interpretation using any of these cell
lines.
Dr Lin. One of the key concepts of CSCs is tumorigenicity.
Out of the 3 cell lines from your data that you presented, 2 of
them formed tumors in the nude mice. The Het-1A did not, for
parent or spheroid cells. However, the 2 markers that you men-
tioned, the Ascl2 and the integrin a6bri/CD71, were both up in
Het-1A. In fact, the integrin a6/CD71 ratio was 21% in Het-
1A and the Ascl2 was up higher than the Johns Hopkins adeno-
carcinoma cell line. What conclusion can you draw about those
markers?
Dr Casson. Your first comment about not being able to grow
Het-1 in animals, that’s consistent with the published data. I
don’t think anybody has been able to reproduce that cell line. So
we really were left with the 2 EADC cell lines for these types of
xenotransplantation experiments.
In terms of the significance of Ascl2 overexpression, at this
point it’s very early. I think what we need to do is reproduce these
results using serial xenograft transplantations along the fairly clas-
sic lines used to determine tumorigenicity using human tissues.
The problem we have, of course, is that the particular marker,
the integrin a6/CD71, the viability of cells based on cell sorting
just does not give you sufficient viability to establish those as xe-
nografts at this point.
Dr Lin. Did you look at any functional studies looking at these
2 genes? Did you try to transfect Ascl2 or integrin a6 to see if it
affects spheroid formation, colony formation, or tumorigenicity?
Dr Casson. No, we haven’t, but that would be the next logical
step.
Dr Lin.My final question: Did you look at any primary tumors
to determine whether either of these markers were overexpressed
in primary tumors?
Dr Casson.We have not looked at the primary tumors. One of
the references I put on from Jan van Lanschot’s lab, that was the
most comprehensive study using primary tumors so far, and, again,
I would say that there were no classic stem cell markers identified
in that series of about 17 tumors. That was reported in the Journal
of Pathology in 2010.
Dr Lin. Thank you. Nice presentation.
Dr Ori Wald (Jerusalem, Israel). I think that another approach
to isolate CSCs might be first to select for chemotherapy resistance
and then to reexamine the markers. I believe that this represents
more what happens in humans. We first treat our patients with che-
motherapy and, as a result, selection for chemotherapy-resistant
cells occurs. By adopting such an approach, this is another ap-
proach you may try to validate the results.
Dr Casson. That’s a good point. I would say that CSC research
for solid tumors, unlike the leukemias, is really in its infancy and
really only has been looked at in the past few years. Good
comment.diovascular Surgery c Volume 144, Number 5 1199
